Brief: Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
14/06/2024 12:38
June 14 (Reuters) - Invivyd Inc IVVD.O :
* INVIVYD ANNOUNCES ANTIVIRAL ACTIVITY OF VYD222
(PEMIVIBART)
AGAINST SARS-COV-2 KP.1.1 FLIRT & KP.3 VARIANTS
* INVIVYD: PSEUDOVIRUS IN VITRO NEUTRALIZATION DATA SHOW
CONTINUED
NEUTRALIZING ACTIVITY OF VYD222 (PEMIVIBART) AGAINST KP.1.1
FLIRT & KP.3 SARS-COV-2
* INVIVYD- SARS-COV-2 MAB CANDIDATE, VYD2311 SHOWS CONTINUED
IN
VITRO NEUTRALIZATION ACTIVITY IN PSEUDOVIRUS ASSAYS AGAINST
KP.1.1 FLIRT, KP.3 VARIANTS
Source text for Eikon: ID:nGNX4mmJ3R
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview